Nuclear Medicine
177Lu PSMA (R+D)
Name:
177Lu PSMA (R+D)
Active Principle:
(2S)-2-[[(1S)-1-carboxy-5-[[(2S)-3-naphthalen-2-yl-2-[[4-[[[2-[4,7,10-tris(carboxymethyl)-1,4,7,10-tetrazacyclododec-1-yl]acetyl]amino]methyl]cyclohexanecarbonyl]amino]propanoyl]amino]pentyl]carbamoylamino]pentanedioic acid
Therapeutic Action:
Radiopharmaceutical used in the treatment of advanced metastatic castration-resistant prostate cancer that presents positive prostate-specific membrane antigen and has not responded effectively to treatment with other anticancer therapies.
Línea
Nuclear Medicine
Sublínea
Radiation Therapy
177Lu PSMA (R+D)
Línea
Nuclear Medicine
Sublínea
Radiation Therapy
177Lu PSMA (R+D)
Nuclear Medicine
177Lu PSMA (R+D)
Name:
177Lu PSMA (R+D)
Active Principle:
(2S)-2-[[(1S)-1-carboxy-5-[[(2S)-3-naphthalen-2-yl-2-[[4-[[[2-[4,7,10-tris(carboxymethyl)-1,4,7,10-tetrazacyclododec-1-yl]acetyl]amino]methyl]cyclohexanecarbonyl]amino]propanoyl]amino]pentyl]carbamoylamino]pentanedioic acid
Therapeutic Action:
Radiopharmaceutical used in the treatment of advanced metastatic castration-resistant prostate cancer that presents positive prostate-specific membrane antigen and has not responded effectively to treatment with other anticancer therapies.
RELATED PRODUCTS
-
131I MIBG BACON (R&D)
131I MIBG BACON (R&D)It is indicated for the diagnosis and location of neuroendocrine tumors, pheochromocytoma, medullary thyroid cancer, primary neuroblastomas and their metastases, paragangliomas and thymomas... -
PARTITION FLASK
PARTITION FLASKVial containing a mixture of solvents to carry out a chromatographic separation ... -
123I MIBG BACON (R&D)
123I MIBG BACON (R&D)It is indicated for: Oncology: a) Scintigraphic localization of tumors originating in tissues that derive embryologically from the neural crest...